Sutro Biopharma, Inc.
STRO· Nasdaq
Released Aug 11, 2026, after the close
10-Q filed Aug 12, 2026, 43 days after period end · 0001193125-26-345748
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $9.84M | $63.75M | $25.71M | $10.41M |
| Net Income | -$38.53M | -$11.50M | -$48.02M | -$38.52M |
| EPS Diluted |
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR
| -$2.33 |
| -$1.35 |
| -$0.59 |
| -$0.64 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.